Advances in the understanding of the Fanconi anemia tumor suppressor pathway
Open Access
- 1 December 2013
- journal article
- review article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 14 (12) , 1089-1091
Abstract
Extremely high cancer incidence in Fanconi anemia (FA) patients has long suggested that the FA signaling pathway is a tumor suppressor pathway. Indeed, our recent findings, for the first time, indicate that the FA pathway plays a significant role in suppressing the development of non-FA human cancer. Also our studies on FA group D2 protein (FANCD2) have, among the first, documented the crosstalks between the FA and Rad6/Rad18 (HHR6) pathways upon DNA damage. In this review, we will discuss how our studies enhance the understanding of the FA tumor suppressor pathway.Keywords
This publication has 42 references indexed in Scilit:
- Mutations in ERCC4, Encoding the DNA-Repair Endonuclease XPF, Cause Fanconi AnemiaThe American Journal of Human Genetics, 2013
- DNA interstrand crosslink repair and cancerNature Reviews Cancer, 2011
- Loss of expression of FANCD2 protein in sporadic and hereditary breast cancerBreast Cancer Research and Treatment, 2007
- PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneNature Genetics, 2006
- A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group MNature Genetics, 2005
- The DNA helicase BRIP1 is defective in Fanconi anemia complementation group JNature Genetics, 2005
- Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemiaLeukemia, 2004
- Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survivalOncogene, 2003
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971